Sirolimus-eluting coronary stent - Micell Technologies

Drug Profile

Sirolimus-eluting coronary stent - Micell Technologies

Alternative Names: MiStent; MiStent SES

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator Micell Technologies
  • Developer Micell Technologies; Stentys
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • Phase III Coronary disorders

Most Recent Events

  • 22 Mar 2016 Micell completes enrolment in MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) study trial for Coronary artery restenosis in USA
  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Micell Technologies completes the DESSOLVE-I trial in Coronary artery restenosis (Prevention) in Australia, Belgium and New Zealand (Intracoronary) (NCT01247428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top